Ads
related to: treatment of hyperparathyroidism
Search results
Results from the WOW.Com Content Network
Hyperparathyroidism is an increase in parathyroid ... it was determined to be related to the parathyroid. [32] Surgery as a treatment was first carried out in 1925. ...
Primary hyperparathyroidism (or PHPT) is a medical condition where the parathyroid gland (or a benign tumor within it) produce excess amounts of parathyroid hormone (PTH). The symptoms of the condition relate to the resulting elevated serum calcium ( hypercalcemia ), which can cause digestive symptoms, kidney stones , psychiatric abnormalities ...
Tertiary hyperparathyroidism is defined by autonomous release of parathyroid hormone while in a hypercalcaemic state. Unlike primary hyperparathyroidism, hypercalcemia in the tertiary form is thought to be the result of resolution of secondary hyperparathyroidism rather than adenoma formation alone. [4] [11] [10]
Secondary hyperparathyroidism is the medical condition of excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to hypocalcemia (low blood calcium levels), with resultant hyperplasia of these glands. This disorder is primarily seen in patients with chronic kidney failure.
Parathyroid auto transplantation is part of the treatment when a patient has hyperparathyroidism and three or four parathyroid glands were already removed, but during the surgery one of the glands (in the case of the removal of three) is relocated at another part of the body to make, the procedure less risky another procedure.
Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. [ 4 ] [ 6 ] [ 5 ] Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues ) by allosteric activation of the calcium-sensing receptor that is ...
In many cases, the parathyroid hormone production improves when these abnormalities are treated with medication. A small proportion, however, have persistently raised hormone levels six months after treatment has started, thought to be autonomous production of hormone by the glands and loss of feedback mechanisms.
Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism. [1] It acts as a calcium-sensing receptor agonist. [2] In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis. [3]
Ads
related to: treatment of hyperparathyroidism